PE20221328A1 - Peptidos ciclicos especificos de receptores unidos a diamina - Google Patents
Peptidos ciclicos especificos de receptores unidos a diaminaInfo
- Publication number
- PE20221328A1 PE20221328A1 PE2022001532A PE2022001532A PE20221328A1 PE 20221328 A1 PE20221328 A1 PE 20221328A1 PE 2022001532 A PE2022001532 A PE 2022001532A PE 2022001532 A PE2022001532 A PE 2022001532A PE 20221328 A1 PE20221328 A1 PE 20221328A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical composition
- cyclic peptides
- binded
- diamine
- receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Esta referido a un peptido ciclico de Formula II, en donde: Xaa1 es -R5-R6; R1 es indol, fenilo o naftilo sustituido o sin sustituir; R2 es -(CH2)u- o -(CH2)v-O-(CH2)w-; R3 es H o una cadena alifatica lineal o ramificada C1 a C9; R4 es -H o -CH3; R7 esta opcionalmente presente y, si esta presente, es de uno a tres aminoacidos de isomero L o D; R8 es H, -(CH2)3, -N(R12a)(R12b), entre otras opciones; R9 es fenilo o naftilo sustituido o sin sustituir; R10 es -N(R12a)(R12b), -NH-(CH2)z-N(R12a)(R12b), -NH-C(=NH)-N(R12a)(R12b), entre otras opciones; x es de 1 a 5; y, t es de 1 a 4. Tambien esta referido a un metodo para el tratamiento de una afeccion o sindrome mediado por el receptor de melanocortina, que comprende la etapa de administrar una composicion farmaceutica que comprende los peptidos ciclicos como se ha expuesto anteriormente. En el metodo de tratamiento, la afeccion o sindrome mediado por el receptor de melanocortina en un ser humano puede ser inflamacion ocular, y la composicion farmaceutica puede ser una composicion farmaceutica acuosa para su administracion en la superficie del ojo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969311P | 2020-02-03 | 2020-02-03 | |
| US202063124927P | 2020-12-14 | 2020-12-14 | |
| PCT/US2021/016007 WO2021158463A1 (en) | 2020-02-03 | 2021-02-01 | Diamine-linked receptor-specific cyclic peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221328A1 true PE20221328A1 (es) | 2022-09-09 |
Family
ID=77200427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001532A PE20221328A1 (es) | 2020-02-03 | 2021-02-01 | Peptidos ciclicos especificos de receptores unidos a diamina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230040236A1 (es) |
| EP (1) | EP4100040A4 (es) |
| JP (1) | JP2023512292A (es) |
| KR (1) | KR20220137043A (es) |
| CN (1) | CN115515617A (es) |
| AU (1) | AU2021216999A1 (es) |
| BR (1) | BR112022015232A2 (es) |
| CA (1) | CA3166466A1 (es) |
| CL (1) | CL2022002073A1 (es) |
| CO (1) | CO2022011468A2 (es) |
| EC (1) | ECSP22068371A (es) |
| IL (1) | IL295151A (es) |
| MX (1) | MX2022009398A (es) |
| PE (1) | PE20221328A1 (es) |
| WO (1) | WO2021158463A1 (es) |
| ZA (1) | ZA202209068B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024040167A2 (en) * | 2022-08-18 | 2024-02-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Selective mc4r ligand for treating obesity and cognitive loss |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6579968B1 (en) * | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
| CN101302246B (zh) * | 2007-05-09 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 黑色素皮质激素受体七肽类激动剂及其制备方法和用途 |
| CN105037502A (zh) * | 2009-06-08 | 2015-11-11 | 帕拉丁科技公司 | 黑皮质素受体特异性肽 |
| EP2440572B1 (en) * | 2009-06-08 | 2017-04-05 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
| WO2017106378A1 (en) * | 2015-12-14 | 2017-06-22 | Aequus Biopharma, Inc. | Melanocortins and methods of use thereof |
| WO2019183472A1 (en) * | 2018-03-23 | 2019-09-26 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery |
-
2021
- 2021-02-01 KR KR1020227029926A patent/KR20220137043A/ko unknown
- 2021-02-01 CN CN202180024924.3A patent/CN115515617A/zh active Pending
- 2021-02-01 JP JP2022547053A patent/JP2023512292A/ja active Pending
- 2021-02-01 WO PCT/US2021/016007 patent/WO2021158463A1/en active Application Filing
- 2021-02-01 CA CA3166466A patent/CA3166466A1/en active Pending
- 2021-02-01 PE PE2022001532A patent/PE20221328A1/es unknown
- 2021-02-01 EP EP21750583.3A patent/EP4100040A4/en active Pending
- 2021-02-01 BR BR112022015232A patent/BR112022015232A2/pt unknown
- 2021-02-01 AU AU2021216999A patent/AU2021216999A1/en active Pending
- 2021-02-01 MX MX2022009398A patent/MX2022009398A/es unknown
- 2021-02-01 IL IL295151A patent/IL295151A/en unknown
-
2022
- 2022-07-11 US US17/811,625 patent/US20230040236A1/en active Pending
- 2022-08-02 CL CL2022002073A patent/CL2022002073A1/es unknown
- 2022-08-12 ZA ZA2022/09068A patent/ZA202209068B/en unknown
- 2022-08-16 CO CONC2022/0011468A patent/CO2022011468A2/es unknown
- 2022-09-01 EC ECSENADI202268371A patent/ECSP22068371A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021216999A1 (en) | 2022-08-25 |
| KR20220137043A (ko) | 2022-10-11 |
| WO2021158463A1 (en) | 2021-08-12 |
| MX2022009398A (es) | 2022-11-07 |
| CO2022011468A2 (es) | 2022-08-30 |
| ECSP22068371A (es) | 2022-10-31 |
| IL295151A (en) | 2022-09-01 |
| JP2023512292A (ja) | 2023-03-24 |
| CL2022002073A1 (es) | 2023-02-24 |
| EP4100040A1 (en) | 2022-12-14 |
| ZA202209068B (en) | 2023-12-20 |
| BR112022015232A2 (pt) | 2022-09-27 |
| US20230040236A1 (en) | 2023-02-09 |
| EP4100040A4 (en) | 2024-06-05 |
| CA3166466A1 (en) | 2021-08-12 |
| CN115515617A (zh) | 2022-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37998A (es) | Agentes antivirales contra la hepatitis b | |
| AR110299A1 (es) | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico | |
| CO2020002980A2 (es) | Agentes antivirales contra la hepatitis b. | |
| CO2020014217A2 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| PE20221328A1 (es) | Peptidos ciclicos especificos de receptores unidos a diamina | |
| DOP2010000143A (es) | Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c | |
| EA025026B1 (ru) | Система подачи невязкого полимерного раствора на основе простагландина, не содержащего консервант | |
| BRPI0418245B8 (pt) | composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes | |
| AR076460A1 (es) | Antagonistas del receptor cxcr3 | |
| AR036854A1 (es) | Composicion de sumunistro de agente de beneficio adecuada para suministrarlo a la superficie de un substrato, composicion de suministro de perfume, producto limpiador, composicion limpiadora, y composicion de tratamiento de tela que lo comprenden | |
| DE602005019853D1 (de) | Pharmazeutische Zusammensetzung mit lyophilisiertem rekombinantem Faktor VIII ohne Albumin als Stabilisator | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| ECSP088159A (es) | Formulaciones de inmunoconjugado | |
| AR068045A1 (es) | Derivados de catecolamina y prodrogas de los mismos | |
| PE20060640A1 (es) | Derivados del acido alcanoico arilcicloalquil-sustituidos y procedimientos para su preparacion | |
| CL2012000715A1 (es) | Compuesto agonista del receptor de peptido natriuretico b (npr-b), que comprende peptidos lineales que contienen 9 residuos aminoacidicos; y su uso para preparar un medicamento para disminuir la presion intraocular. | |
| CL2020002574A1 (es) | Análogos novedosos de glp-1 | |
| CL2018003178A1 (es) | Composición farmacéutica | |
| CO6260099A2 (es) | Depsipeptidos ciclicos | |
| UY39559A (es) | Compuestos y su uso | |
| WO2015183995A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
| AR072072A1 (es) | Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669 | |
| BR0209317A (pt) | Composições incluindo tensoativos com base em vitamina e métodos para usar as mesmas | |
| CO6351716A2 (es) | Formulación de liberación modificada y métodos de uso | |
| KR20110043540A (ko) | 펩티드 유도체 및 이를 포함하는 누액 분비 촉진 조성물 |